Aurinia Pharmaceuticals put cashflow issues behind it on Tuesday, announcing a public offering that it expects will generate $150.5 million in gross proceeds for its Phase 3 trial in lupus nephritis. But not everyone was happy with the news.
Aurinia Pharmaceuticals took an existing drug and made just one amino acid modification. Is it another meaningless iteration, or could this drug really deliver major gains in lupus nephritis?
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Calling Aurinia Pharmaceuticals one happy customer of Philadelphia clinical trial analytics provider Prevail InfoWorks is a gross understatement.
Aurinia was the subject of acquisition rumors in October. Two months later, it's flying solo with $25 million in new financing to power its Phase 3 trial for lupus nephritis.